Indegene Q1FY27: Revenue jumps 40% YoY, consolidated PAT steady at Rs 1,162 mn
INDGN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.3 pts less than Nifty Smallcap 250 and 0.4 pts less than its Healthcare Research Analytics & Technology peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Consolidated revenue rose 39.7% YoY to Rs 10,631 mn in Q1FY27 from Rs 7,608 mn. PAT was nearly flat at Rs 1,162 mn vs Rs 1,164 mn. Standalone revenue grew 33% to Rs 3,407 mn, PAT up 33% to Rs 599 mn. EBITDA margin compressed to about 19% from 23% YoY on higher employee and other costs. Auditor Deloitte gave unmodified opinion. No exceptional items this quarter. Board also approved ESOP allotments under ESOP 2020.
Strong revenue growth but margin pressure; flat consolidated profit may worry investors despite topline beat.